The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patterns of in vitro chemotherapy (CT)-induced apoptosis (APOP) in recurrent/metastatic breast carcinoma (CA): Comparisons of generic multisource drugs (generics) with proprietary single-source drugs (proprietaries).
Linda D. Bosserman
Research Funding - DiaTech Oncology
Karl Rogers
Research Funding - DiaTech Oncology
Dirk C. Davidson
Research Funding - DiaTech Oncology
Carl Rogaston Willis
Research Funding - DiaTech Oncology
James Rutledge
Consultant or Advisory Role - DiaTech Oncology
Allan Hallquist
Employment or Leadership Position - DiaTech Oncology
Stock Ownership - DiaTech Oncology
Tracy Young
No relevant relationships to disclose
Swapnil Padmakar Rajurkar
Research Funding - DiaTech Oncology
Misagh Karimi
Research Funding - DiaTech Oncology
Cary A. Presant
Employment or Leadership Position - DiaTech Oncology
Stock Ownership - DiaTech Oncology
Research Funding - DiaTech Oncology